Seeking Alpha

cptbac

cptbac
Send Message
View as an RSS Feed
Latest  |  Highest rated
  • All Eyes Now Focusing On Acquisition Of Amarin [View instapost]
    Amarin (AMRN -6.4%) trades lower on negative comments out of Summer Street this morning, saying that Vascepa might not be as key as previously thought. The firm notes that a member of AMRN's steering committee presented at a primary care conference last week, and said there was no reason to give Vascepa to patients with triglycerides <500 mg/dL until the outcome of current trials are completed, and, even if approval is granted early, sales are likely to disappoint.

    Key disclaimer:

    "and, even if approval is granted early, sales are likely to disappoint." Although negative coverage, even they are not ruling anything out in terms early approval or on time approval. At this point, much to do about nothing.
    May 28 07:17 PM | Likes Like |Link to Comment
COMMENTS STATS
1 Comment
0 Likes